Crinetics Pharmaceuticals Stock Forecast, Price & News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Crinetics Pharmaceuticals?

Wall Street analysts have given Crinetics Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Crinetics Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, November 5th 2021.
View our earnings forecast for Crinetics Pharmaceuticals.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) posted its quarterly earnings results on Monday, August, 9th. The company reported ($0.70) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.61) by $0.09.
View Crinetics Pharmaceuticals' earnings history.

How has Crinetics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX stock has increased by 35.5% and is now trading at $21.00.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for CRNX?

5 brokers have issued 1-year target prices for Crinetics Pharmaceuticals' stock. Their forecasts range from $28.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $37.00 in the next year. This suggests a possible upside of 76.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:

• Scott R. Struthers, President, Chief Executive Officer & Director
• Jeff E Knight, Chief Operating Officer
• Marc J. S. Wilson, Chief Financial Officer
• Robert Flath, Finance Director
• Alan Seth Krasner, Chief Medical Officer

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Crinetics Pharmaceuticals' key competitors?

Some companies that are related to Crinetics Pharmaceuticals include Cryoport (CYRX), Insmed (INSM), ALX Oncology (ALXO), Intra-Cellular Therapies (ITCI), Aurinia Pharmaceuticals (AUPH), Lyell Immunopharma (LYEL), Amicus Therapeutics (FOLD), Emergent BioSolutions (EBS), Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), Zentalis Pharmaceuticals (ZNTL), PTC Therapeutics (PTCT), Cytokinetics (CYTK), Apellis Pharmaceuticals (APLS) and ACADIA Pharmaceuticals (ACAD).
View all of CRNX's competitors.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Who are Crinetics Pharmaceuticals' major shareholders?

Crinetics Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (13.62%), Perceptive Advisors LLC (10.28%), Perceptive Advisors LLC (10.28%), BlackRock Inc. (6.90%), Bain Capital Life Sciences Investors LLC (4.36%) and Vanguard Group Inc. (4.00%). Company insiders that own Crinetics Pharmaceuticals stock include Matthew K Fust, Perceptive Advisors Llc, Richard Scott Struthers and Vivo Capital Viii, Llc.
View institutional ownership trends for Crinetics Pharmaceuticals.

Which major investors are selling Crinetics Pharmaceuticals stock?

CRNX stock was sold by a variety of institutional investors in the last quarter, including Versant Venture Management LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., JPMorgan Chase & Co., Morgan Stanley, Morgan Stanley, Virtus ETF Advisers LLC, and Victory Capital Management Inc.. Company insiders that have sold Crinetics Pharmaceuticals company stock in the last year include Matthew K Fust, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Crinetics Pharmaceuticals stock?

CRNX stock was acquired by a variety of institutional investors in the last quarter, including Bain Capital Life Sciences Investors LLC, BlackRock Inc., Sphera Funds Management LTD., Vanguard Group Inc., Perceptive Advisors LLC, Perceptive Advisors LLC, Ghost Tree Capital LLC, and FMR LLC. Company insiders that have bought Crinetics Pharmaceuticals stock in the last two years include Perceptive Advisors Llc, and Richard Scott Struthers.
View insider buying and selling activity for Crinetics Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $21.00.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $809.84 million and generates $70,000.00 in revenue each year. The company earns $-73,810,000.00 in net income (profit) each year or ($2.42) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].